NO20076595L - Behandling av leversykdommer hvor jern spiller en rolle i patogenesen - Google Patents

Behandling av leversykdommer hvor jern spiller en rolle i patogenesen

Info

Publication number
NO20076595L
NO20076595L NO20076595A NO20076595A NO20076595L NO 20076595 L NO20076595 L NO 20076595L NO 20076595 A NO20076595 A NO 20076595A NO 20076595 A NO20076595 A NO 20076595A NO 20076595 L NO20076595 L NO 20076595L
Authority
NO
Norway
Prior art keywords
treatment
pathogenesis
role
liver diseases
iron plays
Prior art date
Application number
NO20076595A
Other languages
English (en)
Inventor
Daniele Alberti
Peter Marks
Hanspeter Nick
Lisa Grace Rojkjaer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20076595L publication Critical patent/NO20076595L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Addiction (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Oppfinnelsen angår anvendelse av 4-[3,5-bis-(2-hydroksyfenyl)-[1,2,4]-triazol-1-yl]benzosyre (heretter betegnet som "forbindelse I") for fremstilling av farmasøytiske sammensetninger for behandling av leversykdommer hos menneske der jern spiller en rolle i patagonesen, inkludert virussykdommer slik som kronisk hepatitt C, eventuelt i forbindelse med antivirale midler og for behandling av ikke virale sykdommer slik som ikke-alkoholisk steatohepatitt og ikke-alkoholisk fettleversykdom.
NO20076595A 2005-05-31 2007-12-20 Behandling av leversykdommer hvor jern spiller en rolle i patogenesen NO20076595L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US68584805P 2005-05-31 2005-05-31
US69280805P 2005-06-22 2005-06-22
US74678606P 2006-05-09 2006-05-09
PCT/US2006/020677 WO2006130532A2 (en) 2005-05-31 2006-05-30 Treatment of liver diseases in which iron plays a role in pathogenesis

Publications (1)

Publication Number Publication Date
NO20076595L true NO20076595L (no) 2007-12-20

Family

ID=37106984

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076595A NO20076595L (no) 2005-05-31 2007-12-20 Behandling av leversykdommer hvor jern spiller en rolle i patogenesen

Country Status (16)

Country Link
US (3) US20080199428A1 (no)
EP (1) EP1893198A2 (no)
JP (2) JP2008542380A (no)
KR (2) KR20080003933A (no)
AU (1) AU2006252718B2 (no)
BR (1) BRPI0610873A2 (no)
CA (1) CA2608709A1 (no)
CR (1) CR9454A (no)
EA (1) EA014772B1 (no)
IL (1) IL187000A0 (no)
MA (1) MA29542B1 (no)
MX (1) MX2007015085A (no)
NO (1) NO20076595L (no)
SM (1) SMAP200700061A (no)
TN (1) TNSN07447A1 (no)
WO (1) WO2006130532A2 (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
CA2410579C (en) 2000-05-26 2010-04-20 Jean-Pierre Sommadossi Methods and compositions for treating flaviviruses and pestiviruses
CN1849142A (zh) 2002-11-15 2006-10-18 埃迪尼克斯(开曼)有限公司 2′－支链核苷和黄病毒突变
BRPI0614863A2 (pt) * 2005-08-15 2011-04-19 Hoffmann La Roche uso de conjugados de peg-ifn-alfa em associação a ribavirina, bem como kit compreendendo os mesmos
EP1927591A1 (en) * 2006-11-29 2008-06-04 Novartis AG Polymorphic Forms of Deferasirox (ICL670)
MX2009005619A (es) * 2006-11-29 2009-06-08 Novartis Ag Formas poliformicas del deferasirox (icl670a).
KR102198749B1 (ko) * 2011-03-02 2021-01-06 제롬 쉔타그 단독으로 또는 c형 간염 바이러스 감염과 결합되는 간 지방증의 치료를 위한 조성물, 방법 및 진단
ES2572329B1 (es) 2011-10-21 2017-08-24 Abbvie Inc. Combinación de al menos dos agentes antivirales de acción directa y ribavirina pero no interferón, para uso en el tratamientodel vhc
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
BR112014005617A2 (pt) 2011-10-21 2017-06-13 Abbvie Inc tratamento de combinação (por exemplo, com abt-072 ou abt -333) de daas para uso no tratamento de hcv
CN104023718B (zh) * 2011-10-28 2017-04-05 鲁美纳医药公司 用于治疗高胆血症和胆汁淤积性肝病的胆汁酸再循环抑制剂
CN106488769A (zh) * 2014-03-21 2017-03-08 妥必徕疗治公司 用于治疗纤维化的赛尼克韦罗
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW533205B (en) * 1996-06-25 2003-05-21 Novartis Ag Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
JP4125011B2 (ja) * 2002-01-22 2008-07-23 株式会社 伊藤園 過剰鉄起因肝障害予防・治療剤及び過剰鉄起因肝障害予防・治療飲食物

Also Published As

Publication number Publication date
US20080199428A1 (en) 2008-08-21
CA2608709A1 (en) 2006-12-07
SMAP200700061A (it) 2007-12-28
EP1893198A2 (en) 2008-03-05
US20130109730A1 (en) 2013-05-02
KR20100018057A (ko) 2010-02-16
BRPI0610873A2 (pt) 2010-08-03
JP5869469B2 (ja) 2016-02-24
JP2013082726A (ja) 2013-05-09
KR101174966B1 (ko) 2012-08-17
IL187000A0 (en) 2008-02-09
WO2006130532A2 (en) 2006-12-07
MX2007015085A (es) 2008-01-17
AU2006252718B2 (en) 2010-04-15
KR20080003933A (ko) 2008-01-08
MA29542B1 (fr) 2008-06-02
CR9454A (es) 2008-04-16
AU2006252718A1 (en) 2006-12-07
WO2006130532A3 (en) 2007-11-22
EA200702384A1 (ru) 2008-06-30
TNSN07447A1 (en) 2009-03-17
US20100098662A1 (en) 2010-04-22
EA014772B1 (ru) 2011-02-28
JP2008542380A (ja) 2008-11-27

Similar Documents

Publication Publication Date Title
NO20076595L (no) Behandling av leversykdommer hvor jern spiller en rolle i patogenesen
NO20080284L (no) Cannabionoid aktiv farmasoytisk ingrediens for forbedrede doseringsformer
HRP20150375T1 (hr) Derivati piridazinona
BR0309670A (pt) Compostos derivados dicetohidrazina e drogas contendo os compostos como o ingrediente ativo
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
JP2008540506A5 (no)
MX2010004673A (es) Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrofilos.
BR112017010439A2 (pt) composto, composição farmacêutica, combinação farmacêutica, kit, métodos para controle de uma doença fúngica em uma planta e para prevenção ou tratamento de doença fúngica em um indivíduo, e, uso de um composto
NO20042596L (no) Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1
WO2007128086A3 (en) Novel viral replication inhibitor
UA109421C2 (uk) Фармацевтична композиція, яка містить ліганди сигма-рецептора
NO20085271L (no) Muscarin reseptoragonister som er effektive i behandling av smerte, Alzheimers sykdom og schizofreni
WO2006108682A3 (en) Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use as anti-fungal agents
MA46268B1 (fr) Dérivés de 5-[2-(pyridin-2-ylamino)-1 ,3-thiazol-5-yl]-2,3-dihydro-1h-isoindol-1-one et leur utilisation en tant qu'inhibiteurs doubles de phosphatidylinositol 3-kinase delta & gamma
UA92498C2 (ru) Каннабиноидно активный фармацевтический ингредиент для улучшенных дозированных форм
UY30847A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
NO20063858L (no) Antimikrobielle preservativer for oppnaelse av en multidoseformulering ved bruk av beta-cyklodekstriner for flytende doseringsformer
MA33563B1 (fr) 5-(3,4-dichloro-phényl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-éthoxy)-nicotinamide et ses sels utilisés comme agents augmentant le cholestérol hdl
NO20084913L (no) Sammensetning inneholdende en jernchelator og et anti-neoplatisk middel og anvendelse derav
UY30935A1 (es) Combinacion:-antagonista del receptor de quimioquina 1 (ccr1) -agonista del receptor de glucocorticoides- opcionalmente agonista b(beta)2, -composicion farmacéutica conteniéndola -aplicaciones.
JP2006511538A5 (no)
MA29922B1 (fr) NOUVEAUX DERIVES DE BENZIMIDAZOLES ET BENZOTHIAZOLES, LEUR PROCEDE DE PREPARATION, LEUR APPLICATION A TITRE DE MEDICAMENTS, COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE CMet
WO2006128740A3 (en) Anti-vascular methods and therapies employing lysyl oxidase inhibitors
UY30126A1 (es) Una nueva sal farmaceuticamente aceptable de 2-hidroxi-3-(5-(morfolin-4-ilmetil)-piridin-2-l)1h-indol-5-carbonitrilo, procedimientos para su preparacion, composiciones que la contienen yaplicaciones
UA92912C2 (ru) Способ лечения хронического гепатита с

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application